The Maritime & Commercial Court in Copenhagen has ruled in favor of MAQS’ client BioPorto Diagnostic in a six year long patent litigation against Swedish Padia. The case regarded BioPorto’s revolutionary diagnostic kit for the diagnosis of acute renal failure. Phadia’s European patent for the use of a particular protein in the diagnosis of human diseases was found partially invalid due to lack of inventive step, and the court found that BioPorto’s kit does not infringe the remaining part of the patent.

Attorney Morten Bruus of MAQS Law Firm represented BioPorto:

“It is a very clear verdict from the Maritime & Commercial Court and it paves the way for BioPorto to distribute their revolutionary technology to the benefit of patients all over the world.”

“Additionally, the verdict is historical for the patent community. It is the first time a Danish court finds a European patent partially invalid.”

For further information, please contact Morten Bruus, +4527149544, mbr@dk.maqs.com